Literature DB >> 2433673

The immunodominant epitope of the major membrane tachyzoite protein (P30) of Toxoplasma gondii.

F Santoro, H Charif, A Capron.   

Abstract

Several physicochemical characteristics of the repeated epitope of the major surface protein (P30) of Toxoplasma gondii were investigated with an anti-P30 mAb by two different methods: a one-site/inhibition assay that detects molecules containing single or multiple epitopes and a two-site/one antibody radiometric assay that is only effective with antigenic molecules containing two or more identical epitopes. Using both techniques, the repeated epitope within purified P30 was stable after 1 h at 63 degrees C, but labile at 100 degrees C. It was also resistant to successive freezing and thawing, and not affected after one year at -70 degrees C. Lyophilization and acidic or basic treatment had no effect. This epitope was also resistant to 20% trichloroacetic acid precipitation (activity recovered in the pellet) and to precipitation with cold acetone. To investigate the immunodominance of this repeated epitope during the humoral immune response against T. gondii, competition binding assays between anti-P30 mAb and polyclonal antibodies, from rabbits immunized with either purified P30 or total Toxoplasma extract and from patients with toxoplasmosis, have been used. We found that the mAb inhibited 50-95% of the binding of the IgG antibodies from both rabbits to purified P30. In addition, the binding of both human IgG and IgM antibodies to P30 was significantly inhibited by the mAb. It appears, therefore, that a single region of P30 contains most of the immunogenic activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2433673     DOI: 10.1111/j.1365-3024.1986.tb00876.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  8 in total

1.  Generation of antibodies against Toxoplasma gondii antigen associated with dense granules and the parasitophorous vacuole of the host cell.

Authors:  E Linder; C Thors; F Edberg; S Haglund; C H von Bonsdorff
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

2.  Specific binding of neoglycoproteins to Toxoplasma gondii tachyzoites.

Authors:  R Robert; P L de la Jarrige; C Mahaza; J Cottin; A Marot-Leblond; J M Senet
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

3.  Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to Toxoplasma gondii.

Authors:  J Hackett; J Hoff-Velk; A Golden; J Brashear; J Robinson; M Rapp; M Klass; D H Ostrow; W Mandecki
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Kinetics study and characterisation of target excreted/secreted antigens of immunoglobulin G, M, A and E antibodies from mice infected with different strains of Toxoplasma gondii.

Authors:  P Cazabonne; M H Bessieres; J P Seguela
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

5.  Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies.

Authors:  D Harning; J Spenter; A Metsis; J Vuust; E Petersen
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Improved serological diagnosis of Toxoplasma gondii infection by detection of immunoglobulin A (IgA) and IgM antibodies against P30 by using the immunoblot technique.

Authors:  U Gross; T Roos; D Appoldt; J Heesemann
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

7.  Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis.

Authors:  M F Letillois; V Laigle; F Santoro; M Micoud; B F Chumpitazi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

8.  Identification and characterization of Neospora caninum tachyzoite antigens useful for diagnosis of neosporosis.

Authors:  I Bjerkas; M C Jenkins; J P Dubey
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.